Abstract
A promising area of investigation is the use of cancer vaccines to eliminate residual tumor cells. Dendritic cells (DCs) are potent professional antigen-presenting cells able to induce primary immune responses. DCs capture and process antigens into peptides and present them to T cells and B cells through MHC class I and II molecules. An alternative approach to the induction of antitumor immunity is the use of fusions of DCs and tumor cells. In this approach, a broad spectrum of tumor-associated antigens, including those known and unidentified, are processed endogenously and presented by MHC class I and II pathways in the context of costimulatory signals. In animal studies, vaccination with DC/tumor fusion cells results in the elimination of established lung metastasis. Preclinical human studies have demonstrated that DC/tumor fusion cells induce antigen-specific polyclonal cytotoxic T-lymphocyte responses against autologous tumor in vitro. In clinical studies, vaccination of cancer patients with autologous DC/tumor fusion cells is associated with immunological and clinical responses in a subset of patients. Future studies should be investigated to improve the immunogenicity of DC/tumor fusion cell preparations. This review provides a general overview of the DC/tumor fusion cell-based vaccine and summarizes some of the recent advances in this field.
Article PDF
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Koido, S., Hara, E., Homma, S. et al. Dendritic/tumor fusion cell-based vaccination against cancer. Arch. Immunol. Ther. Exp. 55, 281–287 (2007). https://doi.org/10.1007/s00005-007-0034-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-007-0034-6